Phibro Animal Health (Phibro Animal Health) Days Sales Outstanding : 54.74 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Phibro Animal Health Days Sales Outstanding?

Phibro Animal Health's average Accounts Receivable for the three months ended in Dec. 2023 was $149.9 Mil. Phibro Animal Health's Revenue for the three months ended in Dec. 2023 was $249.9 Mil. Hence, Phibro Animal Health's Days Sales Outstanding for the three months ended in Dec. 2023 was 54.74.

The historical rank and industry rank for Phibro Animal Health's Days Sales Outstanding or its related term are showing as below:

PAHC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.84 Med: 59.74 Max: 65.11
Current: 57.08

During the past 13 years, Phibro Animal Health's highest Days Sales Outstanding was 65.11. The lowest was 54.84. And the median was 59.74.

PAHC's Days Sales Outstanding is ranked better than
65.13% of 1001 companies
in the Drug Manufacturers industry
Industry Median: 71.68 vs PAHC: 57.08

Phibro Animal Health's Days Sales Outstanding declined from Dec. 2022 (54.93) to Dec. 2023 (54.74).

Phibro Animal Health Days Sales Outstanding Historical Data

The historical data trend for Phibro Animal Health's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phibro Animal Health Days Sales Outstanding Chart

Phibro Animal Health Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Days Sales Outstanding

Get a 7-Day Free Trial

64.97

65.11

59.87

60.70

61.59

Phibro Animal Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															54.93	56.56	56.57	61.67	54.74

Competitive Comparison of Phibro Animal Health's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phibro Animal Health's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Phibro Animal Health's Days Sales Outstanding falls into.

Phibro Animal Health Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Phibro Animal Health's Days Sales Outstanding for the fiscal year that ended in Jun. 2023 is calculated as

	Days Sales Outstanding (A: Jun. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )	/	Revenue (A: Jun. 2023 )	*	Days in Period
=	( (166.537	+	163.479)	/	2 )	/	977.889	*	365
=	165.008					/	977.889	*	365
=	61.59

Phibro Animal Health's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (149.228	+	150.627)	/	2 )	/	249.943	*	365 / 4
=	149.9275					/	249.943	*	365 / 4
=	54.74

Phibro Animal Health (NAS:PAHC) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Phibro Animal Health Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Phibro Animal Health's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Phibro Animal Health (Phibro Animal Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Phibro Animal Health Corp (NAS:PAHC) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

PB8:Germany

Address

300 Frank W. Burr Boulevard, Suite 21, 3rd Floor, Glenpointe Centre East, Teaneck, NJ, USA, 07666-6712

Website

https://www.pahc.com

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

Executives

Judith Weinstein	officer: See Remarks	C/O PHIBRO ANIMAL HEALTH CORP, 300 FRANK W. BURR BOULEVARD, STE 21, TEANECK NJ 07666
Alejandro Bernal	director	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
E Thomas Corcoran	director
Larry Lee Miller	officer: Chief Operating Officer	8 HAZELWOOD COURT, WARREN NJ 07059
Damian Finio	officer: Chief Financial Officer	C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Robin Aukerman	officer: President,North America Region	C/O PHIBRO, GLENPOINTE CENTRE EAST, 3RD FL, 300 FRANK W. BURR BLVD, STE 21, TEANECK NJ 07666
Daniel M Bendheim	director, officer: Exec. VP, Corporate Strategy	300 FRANK W. BURR BOULEVARD, SUITE 21, TEANECK NJ 07666
Dean J Warras	officer: Pres Animal Health & Nutr N.A.	5113 SPYGLASS HILL, QUINCY IL 62305
Jack Bendheim	director, 10 percent owner, officer: President and CEO	C/O EMPIRE RESOURCES, INC., 1 PARKER PLAZA, SUIET 10, FORT LEE NJ 07024
Bfi Co., Llc	10 percent owner	300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Jonathan Bendheim	director	GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ 07666
Anthony Andolino	officer: SEE REMARKS	GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Richard G Johnson	officer: Chief Financial Officer	7 WEST 96TH STREET, APT. 11C, NEW YORK NY 10025
Gerald K Carlson	director	2496 OLD BEACH ROAD, WAYZATA MN 55391
Thomas G Dagger	officer: SVP, Gen Counsel and Corp Sec	41 WILCOX DRIVE, MOUNTAIN LAKES NJ 07046